tradingkey.logo
tradingkey.logo
Search

Benitec Biopharma Inc

BNTC
Add to Watchlist
13.220USD
+0.530+4.18%
Close 07/02, 13:00ETQuotes delayed by 15 min
454.16MMarket Cap
LossP/E TTM

TradingKey Stock Score of Benitec Biopharma Inc

Currency: USD Updated: 2026-07-02

Key Insights

Benitec Biopharma Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 46 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.80.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Benitec Biopharma Inc's Score

Industry at a Glance

Industry Ranking
46 / 387
Overall Ranking
132 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Benitec Biopharma Inc Highlights

StrengthsRisks
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -14.33, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 33.05M shares, increasing 13.43% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.36K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.40.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
25.800
Target Price
+103.31%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Benitec Biopharma Inc?

The TradingKey Stock Score provides a comprehensive assessment of Benitec Biopharma Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Benitec Biopharma Inc’s performance and outlook.

How do we generate the financial health score of Benitec Biopharma Inc?

To generate the financial health score of Benitec Biopharma Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Benitec Biopharma Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Benitec Biopharma Inc.

How do we generate the company valuation score of Benitec Biopharma Inc?

To generate the company valuation score of Benitec Biopharma Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Benitec Biopharma Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Benitec Biopharma Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Benitec Biopharma Inc.

How do we generate the earnings forecast score of Benitec Biopharma Inc?

To calculate the earnings forecast score of Benitec Biopharma Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Benitec Biopharma Inc’s future.

How do we generate the price momentum score of Benitec Biopharma Inc?

When generating the price momentum score for Benitec Biopharma Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Benitec Biopharma Inc’s prices. A higher score indicates a more stable short-term price trend for Benitec Biopharma Inc.

How do we generate the institutional confidence score of Benitec Biopharma Inc?

To generate the institutional confidence score of Benitec Biopharma Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Benitec Biopharma Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Benitec Biopharma Inc.

How do we generate the risk management score of Benitec Biopharma Inc?

To assess the risk management score of Benitec Biopharma Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Benitec Biopharma Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Benitec Biopharma Inc.